Clinical Trial

MA+AZA Regimen for the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML)

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
Investigator proposed to apply the new dosage form of mitoxantrone hydrochloride liposomes to the clinical treatment of AML, while combining with cytarabine and azacitidine to form the MA+AZA treatment regimen(Mitoxantrone liposome +Ara-Cytarabine+Azacitidine), which would provide an optimal induction treatment regimen for patients with primary AML by comparing with the traditional chemotherapy regimen, DA+AZA (Daunorubicin+Ara-Cytarabine+Azacitidine).
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-03-26.
Trial Details
NCT Number NCT06345365
Lead Sponsor Zhongnan Hospital
Collaborators: Ruijin Hospital, Shanxi Province Cancer Hospital, The First Affiliated Hospital of Zhengzhou University, Jingzhou Central Hospital, Yichang Central People's Hospital, Taihe Hospital, Central Hospital of Xiaogan, Xianning Central Hospital, The First People's Hospital of Jingzhou
Conditions Acute Myeloid Leukaemia
Enrollment 154 participants
Start Date 2024-01-18
Primary Completion 2026-12-31 (estimated)
Study Completion 2028-12-31 (estimated)
Updated on ClinicalTrials.gov 2024-04-10